A lower dose of the experimental therapy foralumab significantly reduced a marker of brain inflammation in people with nonactive secondary progressive multiple sclerosis (SPMS), according to top-line results from a Phase 2 clinical trial. The 12-week study, called INFORM-MS (NCT06292923), met both its main goals.
Discussion
The experimental oral therapy remibrutinib significantly reduced relapse rates and brain lesion activity more than the approved therapy Aubagio (teriflunomide) in two Phase 3 clinical trials of people with relapsing forms of multiple sclerosis (MS). The trials, REMODEL-1 (NCT05147220) and REMODEL-2 (NCT05156281), compared remibrutinib with…
Discussion
Treatment with rituximab, an anti-CD20 therapy that is used off label for multiple sclerosis (MS), may be associated with a significantly higher risk of developing inflammatory bowel disease (IBD), particularly Crohn’s disease, a large study in Sweden found. After accounting for patient differences, researchers found the risk was…
Discussion
Greater physical disability is associated with poorer cognitive performance in people with multiple sclerosis (MS), particularly in those with more advanced disability, according to a large review and meta-analysis. However, cognitive difficulties may also occur in patients with mild physical impairment, and go undetected by conventional disability assessments. “Cognitive…
Discussion
In a European study of people newly diagnosed with multiple sclerosis (MS), B-cell-depleting treatments were linked to fewer relapses and greater reductions in brain lesion volume over two years compared with oral treatments. However, changes in disability scores were similar across treatment groups.
Get regular updates to your inbox.
